Corporate Background
Immutep is a spin-off from the Gustave Roussy Institute (the largest cancer center clinic in Europe, located South of Paris) and Merck-Serono. It was first incorporated in September 2001. The company's name derived from Imhotep, Doctor, Architect, High Priest, Scribe and Vizier to King Djoser in Ancient Egypt (reigned 2630–2611 BC) who was deified after his death and identified in Greece with the god of medicine, Asclepios.
The company's principal scientific founder, Pr. Frédéric Triebel, M.D., Ph.D., is a senior investigator in both fundamental Immunology and Immunotherapy clinical trials. He cloned the LAG-3 gene in the early 90's and showed subsequently, after 10 years of research, its usefulness as a T-cell response immunostimulant.
The Company is well-advanced in the clinic and is planning a Phase III trial in 2010. It is based near Paris, France, and is staffed with 10 professionals. It has raised € 7.1 million in equity and convertible loans and has been awarded € 1.7 million in grants.
General Information*President & CEO : John B. Hawken, BA Oxon, MBA Scientific and Medical Director : Frédéric Triebel, M.D., Ph.D. Established : September 2001, Immutep, S.A. Headquarters : Immutep, Parc Club Orsay, 2, rue Jean Rostand, 91893 Orsay cedex, FRANCE Laboratories : Immutep, Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, FRANCE. Core Technologies: Chemo-immunotherapy - Active Specific Immunotherapy - Induction and modulation of T cell responses - Therapeutic antibodies Products : IMP321 (ImmuFact® technology), IMP361 and IMP362 (ImmuCcine® technology), IMP701 and IMP731 (ImmuTune® technology) Patents : 53 patents issued Employees : 10, with advanced degrees Financing : Innoven Partenaires, H2I (Paris)
*as of June 9, 2008
